Protein C zymogen in severe sepsis: a double-blinded, placebo-controlled, randomized study
To determine whether protein C zymogen (protein C concentrates or human protein C) improves clinically relevant outcomes in adult patients with severe sepsis and septic shock.
This is a randomized, double-blind, placebo-controlled, parallel-group trial that from September 2012 to June 2014 enrolled adult patients with severe sepsis or septic shock and high risk of death and of bleeding (e.g., APACHE II greater than 25, extracorporeal membrane oxygenation or disseminated intravascular coagulopathy). All patients completed their follow-up 90 days after randomization and data were analyzed according to the intention-to-treat principle. Follow-up was performed at 30 and 90 days after randomization. The primary endpoint was a composite outcome of prolonged intensive care unit (ICU) stay and/or 30-day mortality. Secondary endpoints included mortality.
The study was stopped early in a situation of futility for the composite outcome of prolonged ICU stay and/or 30-day mortality that was 79 % (15 patients) in the protein C zymogen group and 67 % (12 patients) in the placebo group (p = 0.40) and for a concomitant safety issue: ICU mortality was 79 % (15 patients) in the protein C zymogen group vs 39 % (7 patients) in the placebo group (p = 0.020), and 30-day mortality was 68 vs 39 % (p = 0.072).
Protein C zymogen did not improve clinically relevant outcomes in severe sepsis and septic shock adult patients. Given its high cost and the potential increase in mortality, the use of this drug in adult patients should be discouraged.
KeywordsSepsis Critical care Protein C Septic shock Intensive care Mortality
- 1.Zhao H, Heard SO, Mullen MT et al (2012) An evaluation of the diagnostic accuracy of the 1991 American College of Chest Physicians/Society of Critical Care Medicine and the 2001 Society of Critical Care Medicine/European Society of Intensive Care Medicine/American College of Chest Physicians/American Thoracic Society/Surgical Infection Society sepsis definition. Crit Care Med 40:1700–1706. doi:10.1097/CCM.0b013e318246b83a CrossRefPubMedGoogle Scholar
- 6.Vincent JL, Bernard GR, Beale R et al (2005) Drotecogin alfa (activated) treatment in severe sepsis from the global-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277. doi:10.1097/01.CCM.0000181729.46010.83 CrossRefPubMedGoogle Scholar
- 10.Greco M, Landoni G, Nobile L et al (2014) Decreasing mortality with drotrecogin alfa in high risk septic patients A meta-analysis of randomized trials in adult patients with multiple organ failure and mortality >40 %. Signa Vitae 9:16–21Google Scholar
- 13.Landoni G, Monti G, Facchini A et al (2010) Human protein C concentrate in pediatric septic patients. Signa Vitae 5:13–19Google Scholar
- 16.Silvetti S, Crivellari M, Mucchetti M et al (2013) Administration of protein C concentrates in patients without congenital deficit: a systematic review of the literature. Signa Vitae 8:15–19Google Scholar
- 22.(2001) ICH harmonised tripartite guideline: guideline for good clinical practice. 8. Essential documents for the conduct of a clinical trial. J Postgrad Med 47: 264–67Google Scholar
- 24.Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86:1327–1330PubMedGoogle Scholar
- 27.De Kleijn ED, de Groot R, Hack CE et al (2003) Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 31:1839–1847. doi:10.1097/01.CCM.0000072121.61120.D8 CrossRefPubMedGoogle Scholar
- 33.Rintala E, Kauppila M, Seppälä OP et al (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28:2372–2378Google Scholar